key: cord-0977530-sfhdvrmi authors: Venkatesulu, Bhanu Prasad; Thoguluva Chandrasekar, Viveksandeep; Giridhar, Prashanth; V, Pragathee; Patel, Harsh K.; Manteuffel, Jacob title: The mechanistic rationale of drugs, primary endpoints, geographical distribution of clinical trials against severe acute respiratory syndrome‐related coronavirus‐2: A systematic review date: 2020-08-02 journal: J Med Virol DOI: 10.1002/jmv.26338 sha: 230cda0717a27cb3d5cdf294742636b615510276 doc_id: 977530 cord_uid: sfhdvrmi There are numerous ongoing studies assessing treatment options for preventing, treating, and managing complications of coronavirus disease‐2019 disease. The objective of this study was to do a systematic review and critical appraisal of the ongoing clinical trials with an aim to provide insight into the various interventions tested, clinical rationale, geographical distribution of the trials as well as the endpoints assessed in the studies. ClinicalTrials.gov, World Health Organization International Clinical Trials Registry Platform, and PubMed were assessed till 11 May 2020. The search resulted in 3242 ongoing studies of which 829 studies were included. There are 134 different drug‐based interventions being assessed in 463 clinical trials as treatment options China accounts for 35% of all ongoing clinical studies followed by USA 23% and other countries together account for 42%. Amongst the 463 studies assessing drug‐based treatment options, studies that are funded by federal and academic institutions are 79.6%, pharmaceutical company‐funded studies are 15.11%, and no funding information is available in 5.10%. The definitive outcomes like mortality are being assessed as primary outcome in 22.8% of the studies only and need for ventilator in 6.2% of the studies. Amongst the pharmaceutical company‐funded drug‐based studies, only 20% of the studies had mortality as the primary outcome. Only 5.5% of the ongoing clinical trials are specifically designed to assess the most vulnerable population like elderly, patients with comorbidities and cancer. Multiple intervention‐based clinical studies against severe acute respiratory syndrome‐related coronavirus‐2 are being performed throughout the world with a high concentration of clinical trials in the developed world with concern that of elderly and patients with comorbidities are being underrepresented and definite endpoints like mortality are being assessed in only one‐fifth of the studies. Severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) is the causative agent for coronavirus disease-2019 that has led to nearly 13 million new cases and more than a half-million deaths as of 11 July 2020. 1 The case fatality rate is significantly higher in elderly, patients with pre-existing comorbidities, such as hypertension, diabetes, cardiovascular diseases, chronic respiratory disease, and for cancer. [2] [3] [4] [5] The high rate of transmission, moderate case fatality, novel nature of the virus has made the virus a formidable pathogen and has left a huge burden on the healthcare infrastructure. Enormous amount of research is ongoing for finding vaccines, modeling studies, and biological agents to counter the cytokine surge and withspread immune activation. 6, 7 There has also been a surge in interest in repurposing previously approved Food and Drug Administration drugs such as ivermectin, chlorpromazine, isotretinoin, and nitazoxanide for possible antiviral activity. 8, 9 The simultaneous initiation of multiple clinical trials has led to the redundancy of study design, lack of novelty, and absence of pragmatic primary endpoints. We undertook this systematic review of ongoing interventional clinical trials to collate the available information on the study design, geographical distribution, endpoints assessed, and various drugs that are being assessed in the fight against SARS-CoV-2 infections. This systematic review has been performed and reported in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (Supporting Information Data). 10 The data were extracted by two authors independently using a standardized data extraction form based on the SPRINT checklist. The data were extracted on various domains such as trial number, study title, abstract of the study, interventions assessed, sample size, phase of the study, study sponsor, primary endpoint assessed, and country where the study is being done. Any discrepancies in the extraction of data were resolved by mutual discussion (BPV and VTC). We stratified studies into intervention-based studies, observational studies, mathematical modeling studies, studies assessing various diagnostic methods for SARS-CoV-2, studies that assess health services research, epidemiological studies, and studies on pediatric population. is a Canadian study that is assessing colchicine with a primary endpoint of all-cause mortality at day 30. 14 Table 2 provides a summary of phase 3 clinical trials with sample size of more than thousand patients that assess various interventions in COVID-19 disease. Fifty-three drug-based studies are being assessed as prophylaxis in There are currently 42 clinical studies that are assessing mesenchymal stem cell therapy-based interventions in COVID-19 disease. China is leading the initiative with 25 ongoing human trials followed by the USA with eight trials and Spain with four trials. The rationale for the use of mesenchymal stem cells are the hypothesized immunomodulatory properties that can counter the cytokine storm. The various sources of stem cells that are being studied include cord blood, human menstrual blood-derived, mesenchymal stem cells exosomes atomization, human dental pulp, human stromal cells, umbilical cord blood mononuclear cells, and umbilical cord Wharton's Jelly-derived mesenchymal stem cells (Table 4 ). (Table 4 ). There are currently 79 clinical studies assessing the efficacy of alternative medicines mainly the Chinese herbals that are being assessed in 77 studies followed by one study in Iran and one Ayurveda study in UK Table 5 . Supporting Information Data provides a summary of the various ongoing studies that are testing herbal medicines against COVID-19. There are currently 31 ongoing studies that assess various anesthesia-based interventions that include prone positioning, 11 nitric oxide inhalation, 7 ventilator settings, 8 and modified intubation techniques. 5 USA is performing seven studies followed by Canada with five studies. There is excess emotional distress to patients and healthcare providers during the COVID-19 pandemic. There are 18 studies that are assessing mental health-based interventions that include mindfulness (11) meditation (3), intelligent psychosomatic adjustment system (2), cognitive behavioral therapy (1) , and psychological support. China is performing eight studies followed by the USA with four studies. There are currently 12 studies that are assessing various rehabilitation initiatives such as telerehabilitation-based exercises (6), general rehabilitation (2), pulmonary rehabilitation (2) anosmia T A B L E 4 Summary of interventions used in the clinical trials as prevention against severe acute respiratory syndrome coronavirus-2 infection Pre and postexposure prophylaxis There are 32 other intervention-based studies that were not cate- being also studied for its proposed immunogenicity against SARS-CoV-2. 24 Among the drug-based preventive studies, 50% are using HCQ with various aspects being tested including daily vs weekly dosing, pre-vs postexposure prophylaxis. From our review, we feel there is a greater need for more preventive strategy-based studies since most of the countries are reopening and the proposed timeline for the pandemic to subside is 1 to 2 years. 25 CPT use in COVID-19 disease was promoted by the potential efficacy in SARS, MERS, and Ebola. 26 There are currently 56 studies that are ongoing and from some of the published data, it has been shown to be safe and effective. There is a need for information from larger datasets. There are 79 studies that are assessing herbal-based medicines and 42 studies that are assessing mesenchymal stem cells therapy. Majority of these studies are being done in China (%). These interventions are questionable with a potential to harm patients. There is a trend to combine these interventions with western medicines and the potential drug interactions may lead to further adverse events. One of the important aspects that this systematic review shows is the lack of enough studies on rehabilitation and mental health- This is an extensive review of the ongoing clinical studies to give an insight into the various interventions being studied currently. We were also able to identify the outcomes being studied and provide inputs on the need for studies addressing definitive patient-related VENKATESULU ET AL. outcomes like mortality, and need for mechanical ventilation and improvement of patients in the ICU. Our review also provides information regarding the utility of ongoing trials like HCQ-based treatment, which have so far not shown benefit in larger studies, and reassess the need for such studies and utilize resources for other interventions. Newer clinicals are being rapidly initiated and enrolled into the clinical trial registries which makes it difficult for the review to be up to date. Information regarding the status of clinical trials if they are active or have been terminated or completed is not clearly available from the databases. Though the review accounted for most of the clinical trial registries, despite our best attempt, it may not be exhaustive enough to account for retrospective registration of all studies. The majority of ongoing clinical trials seek to enroll patients that may not be representative of the actual population who are at risk of death and morbidity from COVID-19. There needs to be an emphasis on the rationality of the primary endpoints with need for all-cause mortality as the primary endpoint and other patient- An interactive web-based dashboard to track COVID-19 in real time Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention Managing patients with hematological malignancies during COVID-19 pandemic A systematic review and meta-analysis of cancer patients affected by a novel coronavirus COVID-19 in pregnant women and neonates: a systematic review of the literature with quality assessment of the studies Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)-an update on the status Computational models identify several FDA approved or experimental drugs as putative agents against SARS-CoV-2 Boosting the arsenal against COVID-19 through computational drug repurposing Repurposing FDA-approved drugs for COVID-19 using a data-driven approach Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Public Health Emergency SOLIDARITY Trial of Treatments for COVID-19 Infection in Hospitalized Patients Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA). https:// ClinicalTrials.gov/show/NCT04322682 Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION Coronavirus Response-Active Support for Hospitalised Covid-19 Patients Will Hydroxychloroquine Impede or Prevent COVID-19 Biomarkers and surrogate endpoints in clinical trials To whom do the research findings apply? Heart COVID-19: consider cytokine storm syndromes and immunosuppression Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial Data sharing in the era of COVID-19 BCG-induced trained immunity: can it offer protection against COVID-19? Responding to Covid-19-a once-in-a-century pandemic? The use of convalescent plasma to treat emerging infectious diseases: focus on Ebola virus disease The authors would like to thank all the researchers for posting their clinical studies in the clinical trial registries. The authors declare that there are no conflict of interests. BPV conceived the study. VTC, JM, and BPV designed the study. BPV and VTC screened titles and abstracts for inclusion. BPV and VTC extracted and analyzed data. BPV, PG, VP, HKP, and VTC formulated the preliminary draft. BPV guarantees for the data. All authors revised for critical content and approved the final manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. Data used for this article will be provided upon due request to the corresponding author.